Lysiac is a Dutch consultancy specialised in market access, reimbursement and health technology assessment (HTA). Lysiac connects policy insight with practical application to make appropriate treatments available to the right patients. We support organisations with advice, analysis and practical guidance on market access, reimbursement and access-related questions in the Netherlands.
With years of experience and expertise, Lysiac provides insight into complex assessment and decision-making processes for medicines and other treatments. Lysiac brings stakeholders together, creates clarity and helps organisations stay on course in a dynamic international landscape in which the Netherlands plays an important role.
The activities of Lysiac enable the work of Lysiac Institute. Lysiac Institute develops and delivers not-for-profit initiatives, including independent projects and support for parties with limited financial resources, with a clear societal focus.
Lysiac Institute for policy development in healthcare is a
not-for-profit initiative of Lysiac. For more information: Lysiac Institute
Lysiac believes in a healthcare system in which patients have timely and equitable access to appropriate treatments. A sustainable balance between quality and affordability is essential. In a continuously changing environment, it is crucial that policy and practice remain aligned. Transparency, clarity and coherence are necessary conditions to jointly address the challenges of the future.
Lysiac is committed to the socially responsible development and implementation of healthcare policy and practice. With expertise, integrity and engagement, we support organisations in their decisions and actions. We provide strategic insight and practical solutions that contribute to sound decision-making, effective implementation and fair access to care.
Lysiac’s expertise covers the full market access and reimbursement trajectory in the Netherlands — from PICO definition to patient access — with the aim of ensuring timely access to new treatments. Therefore, knowledge and insight into the interaction between systems, procedures and diverse stakeholder interests are essential.
Lysiac works with all relevant stakeholders, including companies, patient organisations, government bodies, health insurers and physicians in the Netherlands. This broad network provides insight into different interests and perspectives. Through policy insight, analysis of policy developments, interpretation of policy adjustments and practical experience, we help bridge differences and translate policy into workable solutions — and vice versa.
The foundation of Lysiac’s expertise is broad knowledge and insight, built on a strong network and years of experience. This includes both regular inpatient and outpatient pathways, as well as specific pathways such as (O)DAP and VT. For new and well-substantiated insights, we can draw on our tools (see Projects).
Reimbursement pathways in the Netherlands and within the BeneluxA collaboration, for example for (orphan) medicines, biotech products, ATMPs and medical technology.
Lysiac pays specific attention to public affairs, communication and coherence throughout the entire reimbursement process to ensure an optimal trajectory. This process starts well before EMA approval: from PICO definition, where applicable via (EU)HTA and (JCA) dossiers, appraisal and (price)agreements, through to patient access.
Lysiac works both on the development of policy and on its application in practice. Through analysis, training, advice and consultancy, we support organisations in building insight, making strategic choices and translating these into practical approaches for complex reimbursement and policy questions.
Analysis and Training
Advice and consultancy
Lysiac has successfully contributed to reimbursement and access for many medicines and treatments across a wide range of disease areas. In addition, Lysiac and Lysiac Institute support the development of policy in this field through projects with umbrella organisations, professional associations and government bodies, as well as through independent scientific initiatives.
To support Lysiac’s mission, we also develop and use a number of content-driven instruments:
Examples of our policy projects, such as (poster)publications you can find here.
Deze tekst weg
Drs. L.G. (Bart) van der Lelie is specialized in policy, media and politics in healthcare
Drs. Evelien Yap, pharmacist, is specialized in market access and reimbursement issues
Lysiac works independently and where appropriate actively seeks collaboration with partner experts and organisations. This ranges from targeted substantive support to participation in larger (potentially international) teams. Lysiac has a strong network of specialised professionals and extensive experience with various forms of collaboration.
FT dossier
FE dossier
FE modelling
AI dossier support
Medical writing
The broad experience and complementary backgrounds of Bart van der Lelie and
Building on this expertise, Lysiac supports organisations in making well-founded decisions in complex policy and reimbursement questions. We combine strategic insight with practical applicability, aiming for clear decision-making, effective implementation and equitable access to care.
Drs. L.G. (Bart) van der Lelie is specialized in policy, media and politics in healthcare
Drs. Evelien Yap, pharmacist, is specialized in market access and reimbursement issues
Lysiac works independently and where appropriate actively seeks collaboration with partner experts and organisations. This ranges from targeted substantive support to participation in larger (potentially international) teams. Lysiac has a strong network of specialised professionals and extensive experience with various forms of collaboration.
The Lysiac DataBase tracks key information on package assessments and the course of reimbursement procedures in the Netherlands. The database contains information on medicines that have undergone a reimbursement procedure, including product characteristics, the assessment, procedural steps, duration and outcomes.
The core
The Lysiac DataBase provides relevant information on real-world cases and reimbursement outcomes and forms a solid basis for analysis and insight into policy trends, with comparable cases offering guidance for the approach to current reimbursement questions.
For more information: info@lysiac.nl
Dutch DO-BO provides a structured and reliable kick-start for pharmacotherapeutic (FT) dossier writing, aligned with the template of Zorginstituut Nederland (ZIN). It supports the development of reimbursement dossiers by efficiently structuring relevant information, allowing teams more room for strategy and refinement.
The core
This results in a kick-start PT dossier: a solid starting point that reduces drafting time and effort.
Data security and confidentiality
DO-BO has been developed in collaboration with MArS and is available for various types of clinical dossiers.
For more information: info@lysiac.nl
The AccessWijzer is a knowledge test and research survey among healthcare professionals, focusing on topics related to health technology assessment (HTA), reimbursement, and market access in the Netherlands. The survey includes specialists and hospital pharmacists and is conducted among the large and active medical panel of Samhealth.
The core
The outcomes provide starting points for dialogue on reimbursement and access and support knowledge development in practice.
Interested in participating or would you like to know more?
Please contact info@lysiac.nl or info@samhealth.nl.
Download the PDF here
Lysiac provides short analyses of key public committee meetings and policy developments in the area of market access and reimbursement in the Netherlands. The analyses combine factual information with interpretation, focused on practical application.
The core
The analyses provide access to relevant policy information and form a solid basis for decision-making, strategic choices and further action.
For more information: info@lysiac.nl
Lysiac was founded in 2010 by Bart van der Lelie, a specialist in healthcare policy. With a background in molecular biology, he works at the intersection of science, policy and practice. He has management experience in the pharmaceutical industry in the areas of HTA, pricing, government relations and communication.
Throughout his career, Bart has been directly involved in policy developments, including as a member of technical consultation of the Dutch Healthcare Authority (NZa) and as chair of various committees and umbrella organisations. By structurally attending and analysing public committee meetings of the House of Representatives, ACP and Zorginstituut Nederland, and by maintaining close contact with stakeholders in the field, he focuses on workable solutions. His goal remains timely access to appropriate treatments for patients.
Evelien Yap has been a partner at Lysiac since 2011 and specialises in reimbursement and access to treatments.
Trained as a pharmacist and holding a master’s degree in health services research, she brings extensive experience from the pharmaceutical industry. Evelien has in-depth expertise in market access, pricing and reimbursement, health economics, negotiations and stakeholder engagement. Combining strategic insight with deep expertise in reimbursement systems and policy developments, underpinned by experience in regulatory affairs, she ensures sound justification for patient access.
Evelien is dedicated to achieving optimal patient access to treatments, guided by an innovative mindset and a strong commitment to quality and integrity.
The Lysiac DataBase tracks key information on package assessments and the course of reimbursement procedures in the Netherlands. The database contains information on medicines that have undergone a reimbursement procedure, including product characteristics, the assessment, procedural steps, duration and outcomes.
The core
The Lysiac DataBase provides relevant information on real-world cases and reimbursement outcomes and forms a solid basis for analysis and insight into policy trends, with comparable cases offering guidance for the approach to current reimbursement questions.
For more information: info@lysiac.nl
Dutch DO-BO provides a structured and reliable kick-start for pharmacotherapeutic (FT) dossier writing, aligned with the template of Zorginstituut Nederland (ZIN). It supports the development of reimbursement dossiers by efficiently structuring relevant information, allowing teams more room for strategy and refinement.
The core
This results in a kick-start PT dossier: a solid starting point that reduces drafting time and effort.
Data security and confidentiality
DO-BO has been developed in collaboration with MArS and is available for various types of clinical dossiers.
For more information: info@lysiac.nl
The AccessWijzer is a knowledge test and research survey among healthcare professionals, focusing on topics related to health technology assessment (HTA), reimbursement, and market access in the Netherlands. The survey includes specialists and hospital pharmacists and is conducted among the large and active medical panel of Samhealth.
The core
The outcomes provide starting points for dialogue on reimbursement and access and support knowledge development in practice.
Interested in participating or would you like to know more?
Please contact info@lysiac.nl or info@samhealth.nl.
Download the PDF here
Lysiac provides short analyses of key public committee meetings and policy developments in the area of market access and reimbursement in the Netherlands. The analyses combine factual information with interpretation, focused on practical application.
The core
The analyses provide access to relevant policy information and form a solid basis for decision-making, strategic choices and further action.
For more information: info@lysiac.nl
Lysiac was founded in 2010 by Bart van der Lelie, a specialist in healthcare policy. With a background in molecular biology, he works at the intersection of science, policy and practice. He has management experience in the pharmaceutical industry in the areas of HTA, pricing, government relations and communication.
Throughout his career, Bart has been directly involved in policy developments, including as a member of technical consultation of the Dutch Healthcare Authority (NZa) and as chair of various committees and umbrella organisations. By structurally attending and analysing public committee meetings of the House of Representatives, ACP and Zorginstituut Nederland, and by maintaining close contact with stakeholders in the field, he focuses on workable solutions. His goal remains timely access to appropriate treatments for patients.
Evelien Yap has been a partner at Lysiac since 2011 and specialises in reimbursement and access to treatments.
Trained as a pharmacist and holding a master’s degree in health services research, she brings extensive experience from the pharmaceutical industry. Evelien has in-depth expertise in market access, pricing and reimbursement, health economics, negotiations and stakeholder engagement. Combining strategic insight with deep expertise in reimbursement systems and policy developments, underpinned by experience in regulatory affairs, she ensures sound justification for patient access.
Evelien is dedicated to achieving optimal patient access to treatments, guided by an innovative mindset and a strong commitment to quality and integrity.
